AM Best has affirmed the Financial Strength Rating (FSR)
of A+ (Superior) and the Long-Term Issuer Credit Ratings (Long-Term
ICR) of “aa-” (Superior) of most members of Metropolitan Life
Insurance Group. In addition, AM Best has upgraded the FSR to A+
(Superior) from A (Excellent) and the Long-Term ICR to “aa-”
(Superior) from “a+” (Excellent) of Metropolitan General Insurance
Company. Concurrently, AM Best has affirmed the Long-Term ICR of
“a-” (Excellent) and the Long- and Short-Term Issue Credit Ratings
(Long-Term IR; Short-Term IR) of MetLife, Inc. (MetLife)
(headquartered in New York, NY) [NYSE: MET]. The outlook of these
Credit Ratings (ratings) is stable. In addition, AM Best has
assigned a Long-Term IR of “a-” (Excellent) to MetLife’s newly
issued $1 billion, 5.25% senior unsecured notes, due 2054. The
outlook assigned to this rating is stable. (See below for a
detailed listing of companies and Long- and Short-Term IRs.)
The ratings reflect Metropolitan Life Insurance Group’s balance
sheet strength, which AM Best assesses as strong, as well as its
strong operating performance, very favorable business profile and
appropriate enterprise risk management (ERM).
Metropolitan Life Insurance Group’s strong balance sheet
assessment is supported by its consolidated view of capital
adequacy that is enhanced by the liquidity and financial
flexibility of its ultimate parent, which historically has
maintained significant and steady levels of excess liquidity.
Additionally, there has been a trend toward reduced liability risk
on the group’s balance sheet, related to equity and interest rate
risk as MetLife’s product portfolio declines over time. Financial
leverage and interest coverage is at appropriate levels for the
ratings.
The group has a history of generating revenue growth and
consistently positive operating metrics on a statutory and GAAP
basis. Earnings are diversified by geography, business line and
distribution channel. Earnings volatility is lower within its group
benefits segment. AM Best views Metropolitan Life Insurance Group’s
operating performance as strong, with the group focused on
enhancing its product offerings, concentrating on higher margin
product lines with lower volatility of returns, and expense
efficiencies. ERM is viewed as appropriate, as the group focuses on
improving its overall program and capital modeling.
The ratings also reflect the organization’s strong, defensible
market positions in its core lines of business and the diversity of
its products and geographic markets in the United States, Asia and
Latin America, as well as the Europe, Middle East and Africa
region.
The FSR of A+ (Superior) and the Long-Term ICRs of “aa-”
(Superior) have been affirmed with stable outlooks for the
following subsidiaries of MetLife, Inc., collectively referred to
as Metropolitan Life Group:
- Delaware American Life Insurance Company
- Metropolitan Life Insurance Company
- Metropolitan Tower Life Insurance Company
- SafeGuard Health Plans, Inc. (TX)
- SafeGuard Health Plans, Inc. (FL)
- SafeGuard Health Plans, Inc. (CA)
- MetLife Global Benefits, Ltd.
The following Short-Term IRs have been affirmed:
MetLife Funding, Inc.— -- AMB-1+ (Strongest) on commercial
paper
MetLife, Inc.— -- AMB-1 (Outstanding) on commercial paper
The following Long-Term IRs have been affirmed with a stable
outlook:
MetLife, Inc.— -- “a-” (Excellent) on USD 1.0 billion 4.368%
senior unsecured debentures, due 2023 -- “a-” (Excellent) on USD
1.0 billion 3.60% senior unsecured notes, due 2024 -- “a-”
(Excellent) on GBP 350 million 5.375% senior unsecured notes, due
2024 -- “a-” (Excellent) on USD 500 million 3.60% senior unsecured
notes, due 2025 -- “a-” (Excellent) on USD 500 million 3.0% senior
unsecured notes, due 2025 -- “a-” (Excellent) on JPY 25.2 billion
0.495% senior unsecured notes, due 2026 -- “a-” (Excellent) on JPY
64.9 billion 0.769% senior unsecured notes, due 2029 -- “a-”
(Excellent) on USD 1.0 billion 4.55% senior unsecured notes, due
2030 -- “a-” (Excellent) on JPY 10.7 billion 0.898% senior
unsecured notes, due 2031 -- “a-” (Excellent) on USD 600 million
6.50% senior unsecured notes, due 2032 -- “a-” (Excellent) on USD
750 million 6.375% senior unsecured notes, due 2034 -- “a-”
(Excellent) on JPY 26.5 billion 1.189% senior unsecured notes, due
2034 -- “a-” (Excellent) on USD 1.0 billion 5.70% senior unsecured
notes, due 2035 -- “a-” (Excellent) on JPY 24.4 billion 1.385%
senior unsecured notes, due 2039 -- “a-” (Excellent) on USD 750
million 5.875% senior unsecured notes, due 2041 -- “a-” (Excellent)
on USD 750 million 4.125% senior unsecured notes, due 2042 -- “a-”
(Excellent) on USD 1.0 billion 4.875% senior unsecured notes, due
2043 -- “a-” (Excellent) on USD 500 million 4.721% senior unsecured
debentures, due 2044 -- “a-” (Excellent) on USD 1.0 billion 4.05%
senior unsecured notes, due 2045 -- “a-” (Excellent) on USD 750
million 4.6% senior unsecured notes, due 2046 -- “a-” (Excellent)
on USD 1 billion 5.0% senior unsecured notes, due 2052 -- “bbb”
(Good) on USD 1.25 billion 6.40% junior subordinated debentures,
due 2066 -- “bbb” (Good) on USD 500 million 10.75% junior
subordinated debentures, due 2069 -- “bbb” (Good) on USD 600
million floating rate non-cumulative preferred stock, Series A --
“bbb” (Good) on USD 500 million 5.875% non-cumulative preferred
stock, Series D -- “bbb” (Good) on USD 805 million 5.625%
non-cumulative preferred stock, Series E -- “bbb” (Good) on USD 1.0
billion 4.75% non-cumulative preferred stock, Series F -- “bbb”
(Good) on USD 1.0 billion 3.85% non-cumulative preferred stock,
Series G
MetLife Capital Trust IV— -- “bbb” (Good) on USD 700 million
7.875% exchangeable surplus trust securities (junior subordinated),
due 2067
Metropolitan Life Insurance Company— -- “a” (Excellent) on USD
250 million 7.80% surplus notes, due 2025 -- “a” (Excellent) on USD
150 million 7.875% surplus notes, due 2024 (originally issued by
New England Mutual Life Insurance Company)
Metropolitan Tower Life Insurance Company— -- “a” (Excellent) on
USD 107 million 7.625% surplus notes, due 2024 (originally issued
by General American Life Insurance Company)
Metropolitan Life Global Funding I—“aa-” (Superior) program
rating -- “aa-” (Superior) on all outstanding notes issued under
the program
The following indicative Long-Term IRs have been affirmed, each
with a stable outlook:
MetLife, Inc. — -- “a-” (Excellent) on senior unsecured debt --
“bbb+” (Good) on subordinated debt -- “bbb” (Good) on preferred
stock
This press release relates to Credit Ratings that have been
published on AM Best’s website. For all rating information relating
to the release and pertinent disclosures, including details of the
office responsible for issuing each of the individual ratings
referenced in this release, please see AM Best’s Recent
Rating Activity web page. For additional information
regarding the use and limitations of Credit Rating opinions, please
view Guide to Best's Credit Ratings. For information
on the proper use of Best’s Credit Ratings, Best’s Performance
Assessments, Best’s Preliminary Credit Assessments and AM Best
press releases, please view Guide to Proper Use of Best’s
Ratings & Assessments.
AM Best is a global credit rating agency, news publisher and
data analytics provider specializing in the insurance industry.
Headquartered in the United States, the company does business in
over 100 countries with regional offices in London, Amsterdam,
Dubai, Hong Kong, Singapore and Mexico City. For more information,
visit www.ambest.com.
Copyright © 2023 by A.M. Best Rating
Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230113005269/en/
Louis Silvers Senior Financial Analyst +1 908
439 2200, ext. 5802 louis.silvers@ambest.com
Christopher Sharkey Manager, Public Relations
+1 908 439 2200, ext. 5159
christopher.sharkey@ambest.com
Jacqalene Lentz, CPA Director +1 908 439 2200,
ext. 5762 jacqalene.lentz@ambest.com
Al Slavin Senior Public Relations Specialist +1
908 439 2200, ext. 5098 al.slavin@ambest.com
MetLife (NYSE:MET)
Historical Stock Chart
From Feb 2023 to Mar 2023
MetLife (NYSE:MET)
Historical Stock Chart
From Mar 2022 to Mar 2023